-
Posted by
Two Blokes Jun 27 -
Filed in
Stock
-
4 views
Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase\u00ae Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase \u00ae" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 4,800,000 share purchase warrants ("Warrants") expiring June 30th, 2025 to June 30th, 2028. The Warrants were issued on June 30th, 2023, pursuant to a private placement involving the issuance of 4,800,000 units of the Company.
